Canaccord Genuity Maintains Buy on Evolent Health, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Neutral 65.8%

Neg 0% Neu 65.8% Pos 0%

Canaccord Genuity analyst Richard Close maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $7 to $6.